Circulating Tumor Cells in Stage IV Melanoma Patients

Hall, Carolyn; Ross, Merrick I.; Bauldry, Jessica B.; Upshaw, Joshua R.; Karhade, Mandar; Royal, Richard E.; Patel, Sapna; Lucci, Anthony

doi:10.1016/j.jamcollsurg.2018.04.026

Cited by 21 publications

(31 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, CTC-negative melanoma patients have been found to have better progression-free or relapse-free survival compared to CTC-positive patients (Hall et al, 2018;Lucci et al, 2020). However, a significant proportion of late-stage melanoma patients still appear to have no CTCs detectable by CellSearch R (Rao et al, 2011;Roland et al, 2015;Hall et al, 2018). This has also been reported for other CSPG4-based methods (Ulmer et al, 2004;Ruiz et al, 2015) as well as for CSPG4-independent isolation methods (Khoja et al, 2014;Aya-Bonilla et al, 2019).…”

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 60%

“…Baseline CTC-positivity independently predicted poorer PFS after 180 days. Hall et al (2018) ≥2 CTCs at baseline was an independent prognostic factor for poor OS. Khoja et al (2013) CXCR4+ CTCs showed potential as a predictive marker for OS in NSCLC patients.…”

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 93%

“…Recently, two large prospective studies also evaluated the prognostic significance of MCAM/CSPG4-positive CTCs in cutaneous melanoma. In a study of 93 stage IV patients, Hall et al (2018) found that presence of CTCs at baseline was associated with shorter progressionfree survival after 6 months compared to CTC-negative patients. Later, the same research group showed that CTC-positivity at baseline for stage III patients (n = 243) was an independent predictor of relapse-free survival within 6 and 54 months (Lucci et al, 2020).…”

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 99%

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 99%

See 3 more Smart Citations

The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis

Ahrens

Bang-Christensen

Jørgensen³

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) are accessible by liquid biopsies via an easy blood draw. They represent not only the primary tumor site, but also potential metastatic lesions, and could thus be an attractive supplement for cancer diagnostics. However, the analysis of rare CTCs in billions of normal blood cells is still technically challenging and novel specific CTC markers are needed. The formation of metastasis is a complex process supported by numerous molecular alterations, and thus novel CTC markers might be found by focusing on this process. One example of this is specific changes in the cancer cell glycocalyx, which is a network on the cell surface composed of carbohydrate structures. Proteoglycans are important glycocalyx components and consist of a protein core and covalently attached long glycosaminoglycan chains. A few CTC assays have already utilized proteoglycans for both enrichment and analysis of CTCs. Nonetheless, the biological function of proteoglycans on clinical CTCs has not been studied in detail so far. Therefore, the present review describes proteoglycan functions during the metastatic cascade to highlight their importance to CTCs. We also outline current approaches for CTC assays based on targeting proteoglycans by their protein cores or their glycosaminoglycan chains. Lastly, we briefly discuss important technical aspects, which should be considered for studying proteoglycans.

show abstract

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 60%

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 93%

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 99%

Section: Proteoglycans In Circulating Tumor Cell Diagnosticsmentioning

confidence: 99%

See 2 more Smart Citations

The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis

Ahrens

Bang-Christensen

Jørgensen³

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…1 In 2018, more than 91 000 individuals were newly diagnosed with melanoma. 2 Most earlystage melanomas (stages I and II) are curable, with a 5-year survival rate of 98.4%. 1 However, advanced melanoma (stages III and IV) with dacarbazine chemotherapy had a low 3-year survival rate of 12.2%.…”

Section: Introductionmentioning

confidence: 99%

Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma

et al. 2020

View full text Add to dashboard Cite

show abstract

Isolation of Circulating Tumor Cells to Diagnose Melanoma and Evaluate the Efficacy of Surgical Resection Using Melanoma‐Specific Microsystem

Kang

Mutukuri

Hadlock

et al. 2022

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Melanoma is one of the most aggressive skin cancers due to its potential to metastasize widely in the body. The risk of metastasis is increased with later detection and increased thickness of the primary lesion, thus early identification/surgical removal is critical for higher survival rates. Recent advances in liquid biopsy have proposed less‐invasive alternatives for cancer diagnosis and monitoring using minimal invasion at sample collection, and circulating tumor cells (CTCs) have been considered a promising blood‐based surrogate marker of primary tumors. Herein, the melanoma‐specific OncoBean platform (MelanoBean) conjugated with melanoma specific antibodies is used. From the comprehensive studies based on change in the number and characteristics of CTCs/CTCs‐clusters pre‐ and post‐surgical treatment, this work demonstrates that melanoma patients (n = 45) at all stages (I–IV) have a noticeable number of CTCs as well as CTC‐clusters compared to healthy donors (n = 9) (p = 0.0011), and surgical treatment leads to a significant decrease in the CTC number (p < 0.0001). The CTCs recovered from the device undergo molecular profiling for melanoma‐associated genes expression using multiplexed qRT‐PCR, demonstrating the ability to monitor molecular signature through treatment. The presented MelanoBean and the comprehensive approach will empower prognostic value of CTCs in melanoma in much larger cohort studies.

show abstract

Circulating Tumor Cells in Stage IV Melanoma Patients

Cited by 21 publications

References 25 publications

The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis

The Role of Proteoglycans in Cancer Metastasis and Circulating Tumor Cell Analysis

Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma

Isolation of Circulating Tumor Cells to Diagnose Melanoma and Evaluate the Efficacy of Surgical Resection Using Melanoma‐Specific Microsystem

Contact Info

Product

Resources

About